Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics

NCT02355574 is registered in ClinicalTrials.gov with Castle Biosciences Incorporated as lead sponsor.

NCT NCT02355574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02355574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics
Lead sponsor
Castle Biosciences Incorporated
Phase
Observational
Overall status
Terminated
Start date
June 30, 2014
Completion date
July 31, 2021
Enrollment
301 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma